Results From Phase I M16-106 Study of Venetoclax Plus Navitoclax in Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

From Clinical Care Options (CCO), download a PDF featuring expert answers to clinician questions on CAR T-cell therapy

Caron A. Jacobson, MD Jae H. Park, MD Noopur Raje, MD Released: July 19, 2021

Drs George Follows, Paolo Ghia, Veronique Leblond discuss the latest clinical data on BTK inhibitors for the treatment of CLL from Clinical Care Options (CCO)

George Follows, BM, BCh, PhD Paolo Ghia, MD, PhD Veronique Leblond, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Released: July 19, 2021 Expired: July 18, 2022

Downloadable slideset with highlights from key blood cancers and nonmalignant blood disorders as presented at EHA Virtual Congress 2021, from Clinical Care Options (CCO)

Prof. Charles Craddock, CBE, FRCP (UK) María-Victoria Mateos, MD, PhD Lydia Scarfò, MD Ali T. Taher, MD, PhD Released: July 16, 2021

Commentary on most important safety and adherence issues to counsel patients starting BTK inhibitors, from Clinical Care Options (CCO)

Beth Faiman, PhD, MSN, APRN-BC, AOCN Released: July 15, 2021